Vivos Therapeutics, Inc.VVOS财报
Beam Therapeutics Inc. is an American biotechnology company conducting research in the field of gene therapies and genome editing. The company is headquartered in Cambridge, Massachusetts. In the development of therapies, the company relies on CRISPR base editing and prime editing, whereby single nucleotides in a DNA sequence can be enzymatically modified without producing double-strand breaks.
VVOS Q4 2025 Key Financial Metrics
营收
$3.8M
毛利润
$3.0M
营业利润
$-6.4M
净利润
$-6.9M
毛利率
78.1%
营业利润率
-166.8%
净利率
-180.3%
同比增长
3.4%
EPS
$-0.58
资金流向
Vivos Therapeutics, Inc. Q4 2025 财务摘要
Vivos Therapeutics, Inc. reported revenue of $3.8M (up 3.4% YoY) for Q4 2025, with a net profit of $-6.9M (down 143.8% YoY) (-180.3% margin). Cost of goods sold was $838.0K, operating expenses totaled $9.4M.
核心财务指标
| 总营收 | $3.8M |
|---|---|
| 净利润 | $-6.9M |
| 毛利率 | 78.1% |
| 营业利润率 | -166.8% |
| 报告期 | Q4 2025 |
营收拆解
Vivos Therapeutics, Inc. Q4 2025 revenue of $3.8M breaks down across 2 segments, led by Services at $3.2M (84.5% of total).
| 业务分部 | 营收 | 占比 |
|---|---|---|
| Services | $3.2M | 84.5% |
| Products | $594.0K | 15.5% |
Vivos Therapeutics, Inc. 分部营收 — 季度趋势
Vivos Therapeutics, Inc. revenue by segment across the last 4 reported quarters, showing how each business line (such as Services and Products) has evolved quarter over quarter.
| 业务分部 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|
| Services | $3.2M | $4.6M | — | — |
| Products | $594.0K | — | $1.9M | $1.8M |
Vivos Therapeutics, Inc. 年度营收
Vivos Therapeutics, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $17.4M). Click any linked year to see what changed vs the prior 10-K.
Vivos Therapeutics, Inc. 季度营收与净利润历史
Vivos Therapeutics, Inc. quarterly results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| 季度 | 营收 | 营收同比 | 净利润 | 净利率 |
|---|---|---|---|---|
| Q4 2025 | $3.8M | +3.4% | $-6.9M | -180.3% |
| Q3 2025 | $6.8M | +75.7% | $-5.4M | -79.6% |
| Q2 2025 | $3.8M | -5.8% | $-5.0M | -131.2% |
| Q1 2025 | $3.0M | -11.8% | $-3.9M | -128.1% |
| Q4 2024 | $3.7M | +13.9% | $-2.8M | -76.4% |
| Q3 2024 | $3.9M | +16.9% | $-2.6M | -67.8% |
| Q2 2024 | $4.1M | +19.4% | $-1.9M | -47.6% |
| Q1 2024 | $3.4M | -11.4% | $-3.8M | -110.1% |
利润表
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| 营收 | $3.4M | $4.1M | $3.9M | $3.7M | $3.0M | $3.8M | $6.8M | $3.8M |
| 同比增长 | -11.4% | 19.4% | 16.9% | 13.9% | -11.8% | -5.8% | 75.7% | 3.4% |
资产负债表
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| 总资产 | $11.8M | $15.8M | $15.3M | $15.3M | $11.3M | $26.0M | $25.6M | $25.2M |
| 总负债 | $11.2M | $9.5M | $7.7M | $7.3M | $6.9M | $21.4M | $23.1M | $26.7M |
| 股东权益 | $582000 | $6.3M | $7.7M | $8.0M | $4.4M | $4.6M | $2.5M | $-1.5M |
现金流量表
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| 经营性现金流 | $-2.5M | $-3.0M | $-4.2M | $-2.9M | $-3.8M | $-3.5M | $-4.2M | $-3.8M |